Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Semaglutide Shows Efficacy in Improving Heart Failure Symptoms and Weight Management in Diabetic Patients

Recent research investigates the impact of semaglutide on patients suffering from obesity-related heart failure with preserved ejection fraction who also have type 2 diabetes. This study adds to the growing body of literature that evaluates the intersection of diabetes management and cardiovascular health.

Study Design:

  • Participants: 616 patients with heart failure with preserved ejection fraction (HFpEF), a body mass index of 30 or more, and type 2 diabetes.
  • Procedure: Patients were randomly assigned to receive either semaglutide (2.4 mg) or a placebo once weekly for 52 weeks.
  • Primary Measures: Changes in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) and body weight were the primary endpoints.
  • Secondary Measures: Confirmatory secondary endpoints included changes in 6-minute walk distance, a hierarchical composite endpoint of death, heart failure events, and other clinical measures, along with changes in C-reactive protein (CRP) levels.

Key Findings:

  • Symptom Improvement: Semaglutide recipients experienced an average increase of 13.7 points in the KCCQ-CSS compared to 6.4 points for the placebo group.
  • Weight Loss: The semaglutide group saw an average body weight reduction of 9.8%, significantly greater than the 3.4% reduction in the placebo group.
  • Exercise Capacity: There was an improved 6-minute walk distance by 14.3 meters in the semaglutide group over placebo.
  • Composite Endpoint: The win ratio for the hierarchical composite endpoint favored semaglutide significantly, suggesting overall clinical benefits.
  • Inflammation Reduction: CRP levels decreased more in the semaglutide group, indicating reduced inflammation.
  • Safety Profile: Fewer serious adverse events were reported in the semaglutide group (17.7%) compared to the placebo group (28.8%).

HCN Medical Memo
Semaglutide appears to offer multiple therapeutic benefits for patients at the intersection of diabetes and heart failure, a challenging cohort to manage due to their complex clinical needs. This study emphasizes the potential of targeted therapies in improving quality of life and reducing the burden of symptoms in these patients.

More in Endocrinology, Diabetes & Metabolism

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form